Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer

An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)

Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,626 · see citing works

Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor

Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,533 · see citing works

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · see citing works

15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ

FORMAN, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858 · see citing works

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217 · see citing works

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation

Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028 · see citing works

PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development

Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y., Ruiz‐Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,960 · see citing works

Roles of PPARs in health and disease

Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · see citing works

Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ

Picard, F., Kurtev, M. V., Chung, N., Topark‐Ngarm, A., Senawong, T., de Oliveira, R. M., Leid, M. E., McBurney, M. W., & Guarente, L. (2004) · Nature · doi:10.1038/nature02583 · Cited by 1,943 · see citing works

Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism

Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · see citing works

Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase

Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310 · see citing works

The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene

Lluis Fajas, A., Auboeuf, D., Raspé, E., Schoonjans, K., Lefebvre, A., Saladin, R., Najib, J., Laville, M., Fruchart, J., Deeb, S. S., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18779 · Cited by 1,188 · see citing works

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,170 · see citing works

PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs

He, T., Chan, T. A.-T., Vogelstein, B., & Kinzler, K. W. (1999) · Cell · doi:10.1016/s0092-8674(00)81664-5 · Cited by 1,083 · see citing works

PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069 · see citing works

15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway

Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 1,004 · see citing works

The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene

Tugwood, J. D., Issemann, I., Anderson, R. G., Bundell, K. R., McPheat, W. L., & Green, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05072.x · Cited by 895 · see citing works

Terminal Differentiation of Human Breast Cancer through PPARγ

Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., & Spiegelman, B. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80047-7 · Cited by 850 · see citing works

Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

Elstner, E., Müller‐Tidow, C., Koshizuka, K., Williamson, E. A., Park, D. J., Asou, H., Shintaku, P. I., SAID, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 805 · see citing works

PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma

Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 780 · see citing works

Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha.

Hu, E., Tontonoz, P., & Spiegelman, B. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9856 · Cited by 658 · see citing works

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor

Tontonoz, P., Singer, S., FORMAN, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. �., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 654 · see citing works

Activation of PPARγ Coactivator-1 Through Transcription Factor Docking

Puigserver, P., Adelmant, G., Wu, Z., Fan, M., Xu, J., O’Malley, B. W., & Spiegelman, B. M. (1999) · Science · doi:10.1126/science.286.5443.1368 · Cited by 596 · see citing works

Peroxisome-proliferator-activated receptors and cancers: complex stories

Michalik, L., Desvergne, B., & Wahli, W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1254 · Cited by 574 · see citing works

Peroxisome Proliferator-activated Receptor γ Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in Vivo

Xin, X., Yang, S., Kowalski, J., & Gerritsen, M. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.9116 · Cited by 508 · see citing works

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma

Demetri, G. D., Fletcher, C. D. �., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., & Singer, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3951 · Cited by 495 · see citing works

Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids

Schmidt, A., Endo, N., Rutledge, S. J., Vogel, R., SHINAR, D. M., & Rodan, G. A. (1992) · Molecular Endocrinology · doi:10.1210/mend.6.10.1333051 · Cited by 476 · see citing works

Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists

Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 440 · see citing works

Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer

Mueller, E., Smith, M. R., Sarraf, P., Kroll, T. G., Aiyer, A., Kaufman, D. S., Oh, W. K., Demetri, G. D., Figg, W. D., Zhou, X.-P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180329197 · Cited by 427 · see citing works

Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects

Berger, J. P., Leibowitz, M. D., Doebber, T. W., Elbrecht, A., Zhang, B., Zhou, G., Biswas, C., Cullinan, C. A., Hayes, N. S., Li, Y., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6718 · Cited by 412 · see citing works

Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)<b>α</b> and PPAR<b>β</b> mutant mice

Michalik, L., Desvergne, B., Tan, N. S., Basu-Modak, S., Escher, P., Rieusset, J., Peters, J. M., Kaya, G., Gonzalez, F. J., Zakany, J., et al. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200011148 · Cited by 406 · see citing works

PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2APreprint

Altiok, S., Xu, M. J., & Spiegelman, B. M. (1997) · Genes & Development · doi:10.1101/gad.11.15.1987 · Cited by 378 · see citing works

Peroxisome proliferator-activated receptor gamma and cancers.

Koeffler, H. P. (2003) · PubMed · Cited by 347 · see citing works

Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators

Westin, S. K., Kurokawa, R., Nolte, R. T., Wisely, G. B., McInerney, E. M., Rose, D. W., Milburn, M. V., Rosenfeld, M. G., & Glass, C. K. (1998) · Nature · doi:10.1038/26040 · Cited by 333 · see citing works

Transcription coactivator TRAP220 is required for PPARγ2-stimulated adipogenesis

Ge, K., Guermah, M., Yuan, C., Ito, M., Wallberg, A. E., Spiegelman, B. M., & Roeder, R. G. (2002) · Nature · doi:10.1038/417563a · Cited by 319 · see citing works

Role of PPARγ in Regulating a Cascade Expression of Cyclin-dependent Kinase Inhibitors, p18(INK4c) and p21(Waf1/Cip1), during Adipogenesis

Morrison, R. F., & Farmer, S. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17088 · Cited by 313 · see citing works

A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation

Oberfield, J. L., Collins, J. L., Holmes, C. P., Goreham, D. M., Cooper, J. P., Cobb, J. E., Lenhard, J. M., Hull-Ryde, E. A., Mohr, C. P., Blanchard, S. G., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6102 · Cited by 311 · see citing works

The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs

Issemann, I., Prince, R. A., Tugwood, J. D., & Green, S. (1993) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0110037 · Cited by 307 · see citing works

The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling

Shi, Y., Hon, M., & Evans, R. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052707099 · Cited by 304 · see citing works

Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.

Palakurthi, S. S., Aktaş, H., Grubissich, L., Mortensen, R. M., & Halperin, J. A. (2001) · PubMed · Cited by 301 · see citing works

Metabolic and Additional Vascular Effects of Thiazolidinediones

Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 289 · see citing works

PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Panigrahy, D., Singer, S., Shen, L. Q., Butterfield, C., Freedman, D. A., Chen, E. J., Moses, M. A., Kilroy, S. M., Duensing, S. M., Fletcher, C. D. �., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215634 · Cited by 276 · see citing works

Cyclin D1 Inhibits Peroxisome Proliferator-activated Receptor γ-mediated Adipogenesis through Histone Deacetylase Recruitment

Fu, M., Rao, M., Bouras, T., Wang, C., Wu, K., Zhang, X., Li, Z., Yao, T., & Pestell, R. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500403200 · Cited by 274 · see citing works

Coordination of p300-Mediated Chromatin Remodeling and TRAP/Mediator Function through Coactivator PGC-1α

Wallberg, A. E., Yamamura, S., Malik, S., Spiegelman, B. M., & Roeder, R. G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00391-5 · Cited by 247 · see citing works

Genetic disruption of PPAR δ decreases the tumorigenicity of human colon cancer cells

Park, B. H., Vogelstein, B., & Kinzler, K. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051630998 · Cited by 247 · see citing works

Genetic Analysis of Adipogenesis through Peroxisome Proliferator-activated Receptor γ Isoforms

Mueller, E., Drori, S., Aiyer, A., Yie, J., Sarraf, P., Chen, H., Hauser, S., Rosen, E. D., Ge, K., Roeder, R. G., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206950200 · Cited by 246 · see citing works

The Nuclear Receptor Corepressors NCoR and SMRT Decrease Peroxisome Proliferator-activated Receptor γ Transcriptional Activity and Repress 3T3-L1 Adipogenesis*

Yu, C., Markan, K. R., Temple, K. A., Deplewski, D., Brady, M., & Cohen, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409468200 · Cited by 243 · see citing works

A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.

Suh, N., Wang, Y., Williams, C. R., Risingsong, R., Gilmer, T. M., Willson, T. M., & Sporn, M. B. (1999) · PubMed · Cited by 230 · see citing works

Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

Burstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., & Winer, E. P. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024038127156 · Cited by 228 · see citing works

Thiazolidenediones Mediate Apoptosis in Prostate Cancer Cells in Part through Inhibition of Bcl-xL/Bcl-2 Functions Independently of PPARγ

Shiau, C., Yang, C.-C., Kulp, S. K., Chen, K., Chen, C., Huang, J., & Chen, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1677 · Cited by 222 · see citing works

Peroxisome proliferator–activated receptor-δ attenuates colon carcinogenesis

Harman, F. S., Nicol, C. J. B., Marin, H. E., Ward, J. M., Gonzalez, F. J., & Peters, J. M. (2004) · Nature Medicine · doi:10.1038/nm1026 · Cited by 214 · see citing works

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

Kohlroser, J., Mathai, J., Reichheld, J., Banner, B. F., & Bonkovsky, H. L. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01707.x · Cited by 209 · see citing works

In vivo activation of PPAR target genes by RXR homodimers

IJpenberg, A., Tan, N. S., Gelman, L., Kersten, S., Seydoux, J., Xu, J., METZGER, D., Canaple, L., Chambon, P., Wahli, W., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600209 · Cited by 208 · see citing works

A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties*

Reginato, M., Bailey, S., Krakow, S. L., Minami, C., Ishii, S., Tanaka, H., & Lazar, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32679 · Cited by 195 · see citing works

Cyclin D1 Repression of Peroxisome Proliferator-Activated Receptor γ Expression and Transactivation

Wang, C., Pattabiraman, N., Zhou, J., Fu, M., Sakamaki, T., Albanese, C., Li, Z., Wu, K., Hulit, J., Neumeister, P., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6159-6173.2003 · Cited by 195 · see citing works

GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation

Seargent, J. M., Yates, E., & Gill, J. H. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705973 · Cited by 193 · see citing works

Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.

Rubin, G., Zhao, Y., Kalus, A. M., & Simpson, E. R. (2000) · PubMed · Cited by 190 · see citing works

Transcriptional Activity of Peroxisome Proliferator-activated Receptor γ Is Modulated by SUMO-1 Modification

Ohshima, T., Koga, H., & Shimotohno, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403866200 · Cited by 185 · see citing works

Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells

Clay, C. E., Namen, A. M., Atsumi, G., Willingham, M. C., High, K. P., Kute, T. E., Trimboli, A. J., Fonteh, A. N., Dawson, P. A., & Chilton, F. H. (1999) · Carcinogenesis · doi:10.1093/carcin/20.10.1905 · Cited by 184 · see citing works

Activation of Peroxisome Proliferator-Activated Receptor δ Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines

Stephen, R. L., Gustafsson, M. C. U., Jarvis, M. C., Tatoud, R., Marshall, B. R., Knight, D. A., Ehrenborg, E., Harris, A. L., Wolf, C. R., & Palmer, C. N. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2760 · Cited by 181 · see citing works

Loss of the Peroxisome Proliferation-activated Receptor gamma (PPARγ) Does Not Affect Mammary Development and Propensity for Tumor Formation but Leads to Reduced Fertility

Cui, Y., Miyoshi, K., Claudio, E., Siebenlist, U. K., Gonzalez, F. J., Flaws, J. A., Wagner, K., & Hennighausen, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200186200 · Cited by 180 · see citing works

PPARγ signaling exacerbates mammary gland tumor developmentPreprint

Sáez, E., Rosenfeld, J. M., Livolsi, A., Olson, P., Lombardo, E., Nelson, M. C., Banayo, E., Cardiff, R. D., Izpisúa‐Belmonte, J. C., & Evans, R. M. (2004) · Genes & Development · doi:10.1101/gad.1167804 · Cited by 178 · see citing works

PPARγ Ligands and ATRA Inhibit the Invasion of Human Breast Cancer Cells in vitro

Liu, H., Zang, C., Fenner, M. H., Possinger, K., & Elstner, E. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023366117157 · Cited by 169 · see citing works

Leptin Induces Endothelial Cell Migration Through Akt, Which Is Inhibited by PPARγ-Ligands

Goetze, S., Bungenstock, A., Czupalla, C., Eilers, F., Stawowy, P., Kintscher, U., Spencer-Hänsch, C., Graf, K., Nürnberg, B., Law, R. E., et al. (2002) · Hypertension · doi:10.1161/01.hyp.0000035522.63647.d3 · Cited by 169 · see citing works

Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells.

Qin, C., Burghardt, R. C., Smith, R., Wormke, M., Stewart, J., & Safe, S. H. (2003) · PubMed · Cited by 167 · see citing works

Amplification and overexpression of peroxisome proliferatoractivated receptor binding protein ( PBP/PPARBP ) gene in breast cancer

Zhu, Y., Qi, C., Jain, S. R., Beau, M. M. L., Espinosa, R., Atkins, G. B., Lazar, M. A., Yeldandi, A. V., Rao, M. S., & Reddy, J. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10848 · Cited by 166 · see citing works

Inhibition of Cellular Proliferation through IκB Kinase-Independent and Peroxisome Proliferator-Activated Receptor γ-Dependent Repression of Cyclin D1

Wang, C., Fu, M., D’Amico, M., Albanese, C., Zhou, J., Brownlee, M., Lisanti, M. P., Chatterjee, K., Lazar, M. A., & Pestell, R. G. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.9.3057-3070.2001 · Cited by 165 · see citing works

Expression of peroxisome‐proliferator activated receptor‐gamma (PPARγ) and the PPARγ co‐activator, PGC‐1, in human breast cancer correlates with clinical outcomes

Jiang, W. G., Douglas‐Jones, A. G., & Mansel, R. E. (2003) · International Journal of Cancer · doi:10.1002/ijc.11302 · Cited by 162 · see citing works

A phase II trial with rosiglitazone in liposarcoma patients

Debrock, G., Vanhentenrijk, V., Sciot, R., Dêbiec‐Rychter, M., Oyen, R., & van Oosterom, A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601306 · Cited by 161 · see citing works

The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.

Wu, K., Zhang, Y., Xu, X., Hill, J. L., Celestino, J., Kim, H.-T., Mohsin, S. K., Hilsenbeck, S. G., Lamph, W. W., Bissonette, R., et al. (2002) · PubMed · Cited by 158 · see citing works

A Phase II Study of Troglitazone, an Activator of the PPAR?? Receptor, in Patients with Chemotherapy-Resistant Metastatic Colorectal Cancer

Kulke, M. H., Demetri, G. D., Sharpless, N. E., Ryan, D. P., Shivdasani, R. A., Clark, J. S., Spiegelman, B. M., Kim, H. T., Mayer, R. J., & Fuchs, C. S. (2002) · The Cancer Journal · doi:10.1097/00130404-200209000-00010 · Cited by 150 · see citing works

The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.

Place, A. E., Suh, N., Williams, C. R., Risingsong, R., Honda, T., Honda, Y., Gribble, G. W., Leesnitzer, L. M., Stimmel, J. B., Willson, T. M., et al. (2003) · PubMed · Cited by 147 · see citing works

A Ligand of Peroxisome Proliferator-Activated Receptor gamma, Retinoids, and Prevention of Preneoplastic Mammary Lesions

Mehta, R. G. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.418 · Cited by 147 · see citing works

Troglitazone Inhibits Growth of MCF-7 Breast Carcinoma Cells by Targeting G1 Cell Cycle Regulators

Yin, F., Wakino, S., Liu, Z., Kim, S., Hsueh, W. A., Collins, A. R., Herle, A. J. V., & Law, R. E. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5491 · Cited by 143 · see citing works

Peroxisome proliferator–activated receptor α in the human breast cancer cell lines MCF‐7 and MDA‐MB‐231

Suchanek, K. M., May, F. J., Robinson, J. A., Lee, W. J., Holman, N. A., Monteith, G. R., & Roberts‐Thomson, S. J. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10061 · Cited by 141 · see citing works

Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies.

Ikezoe, T., Cw, M., Kawano, S., Heaney, A. P., Williamson, E. A., Hisatake, J., Green, E., Hofmann, W., Taguchi, H., & Hp, K. (2001) · PubMed · Cited by 139 · see citing works

Ciglitazone, a New Hypoglycemic Agent: I. Studies in ob/ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic Rats

Chang, A. Y., Wyse, B. M., Gilchrist, B. J., Peterson, T., & Diani, A. R. (1983) · Diabetes · doi:10.2337/diab.32.9.830 · Cited by 138 · see citing works

Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators

Theocharis, S., Margeli, A. P., Vielh, P. R., & Kouraklis, G. P. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.04.004 · Cited by 135 · see citing works

Role of peroxisome proliferator-activated receptor- (PPAR ) in bezafibrate-induced hepatocarcinogenesis and cholestasis

Hays, T. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh285 · Cited by 130 · see citing works

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy

Smith, M. R., Manola, J. B., Kaufman, D. S., George, D. J., Oh, W. K., Mueller, E., Slovin, S. F., Spiegelman, B. M., Small, E. J., & Kantoff, P. W. (2004) · Cancer · doi:10.1002/cncr.20493 · Cited by 124 · see citing works

Peroxisome Proliferator-Activated Receptor γ-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells

Huang, J., Shiau, C., Yang, Y.-T. C., Kulp, S. K., Chen, K., Brueggemeier, R. W., Shapiro, C. L., & Chen, C. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.007732 · Cited by 124 · see citing works

Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer

Esteva, F. J., Glaspy, J. A., Baidas, S. M., Laufman, L. R., Hutchins, L. F., Dickler, M. N., Tripathy, D., Cohen, R., DeMichele, A. M., Yocum, R. C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.068 · Cited by 115 · see citing works

Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.

Tong, W., Ding, X., Hennig, R., Witt, R. C., Standop, J., Pour, P. M., & Adrian, T. E. (2002) · PubMed · Cited by 114 · see citing works

AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats

Ljung, B., Bamberg, K., Dahllöf, B., Kjellstedt, A., Oakes, N. D., Östling, J., Svensson, L., & Camejo, G. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200127-jlr200 · Cited by 110 · see citing works

Design and Synthesis of N -[(4-Methoxyphenoxy)carbonyl]- N -[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities

Devasthale, P. V., Chen, S., Jeon, Y. T., Qu, F., Shao, C., Wang, W., Zhang, H., Cap, M., Farrelly, D., Golla, R., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0496436 · Cited by 108 · see citing works

Peroxisome Proliferator-activated Receptor γ Agonists Promote TRAIL-induced Apoptosis by Reducing Survivin Levels via Cyclin D3 Repression and Cell Cycle Arrest

Lü, M., Kwan, T., Yu, C., Chen, F., Freedman, B. D., Schafer, J. M., Lee, E. J., Jameson, J. L., Jordan, V. C., & Cryns, V. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411519200 · Cited by 103 · see citing works

15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells

Clay, C. E., Monjazeb, A., Thorburn, J., Chilton, F. H., & High, K. P. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200224-jlr200 · Cited by 103 · see citing works

A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes.

Qin, C., Morrow, D., Stewart, J., Spencer, K., Porter, W. W., Smith, R., Phillips, T. D., Abdelrahim, M., Samudio, I. J., & Safe, S. H. (2004) · PubMed · Cited by 103 · see citing works

Differential Expression of the Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Its Coactivators Steroid Receptor Coactivator-1 and PPAR-Binding Protein PBP in the Brown Fat, Urinary Bladder, Colon, and Breast of the Mouse

Jain, S. R., Pulikuri, S., Zhu, Y., Qi, C., Kanwar, Y. S., Yeldandi, A. V., Rao, M. S., & Reddy, J. K. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65577-0 · Cited by 102 · see citing works

L-764406 Is a Partial Agonist of Human Peroxisome Proliferator-activated Receptor γ

Elbrecht, A., Chen, Y., Adams, A., Berger, J. P., Griffin, P. R., Klatt, T., Zhang, B., Menke, J. G., Zhou, G., Smith, R. G., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7913 · Cited by 102 · see citing works

A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands

Crowe, D. L., & Chandraratna, R. A. S. (2004) · Breast Cancer Research · doi:10.1186/bcr913 · Cited by 101 · see citing works

Combining Radiation and Molecular Targeting in Cancer Therapy

Camphausen, K., & Tofilon, P. J. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.3.544 · Cited by 93 · see citing works

The Antidiabetic Agent Thiazolidinedione Stimulates the Interaction between PPARγ and CBP

Mizukami, J., & Taniguchi, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7602 · Cited by 92 · see citing works

Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells

Yin, F., Bruemmer, D., Blaschke, F., Hsueh, W. A., Law, R. E., & Herle, A. J. V. (2004) · Oncogene · doi:10.1038/sj.onc.1207598 · Cited by 89 · see citing works

Therapeutic potential of thiazolidinediones as anticancer agents

Panigrahy, D., Shen, L. Q., Kieran, M. W., & Kaipainen, A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.12.1925 · Cited by 88 · see citing works

Peroxisome Proliferator Activated Receptor-γ (PPAR-γ) Ligands and Angiogenesis

Margeli, A. P., Kouraklis, G. P., & Theocharis, S. E. (2003) · Angiogenesis · doi:10.1023/b:agen.0000021377.13669.c0 · Cited by 82 · see citing works

Novel Therapeutic Approach: Ligands for PPARγ and Retinoid Receptors Induce Apoptosis in bcl-2-positive Human Breast Cancer Cells

Elstner, E., Williamson, E., Zang, C., Fritz, J., Heber, D., Fenner, M. H., Possinger, K., & Koeffler, H. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1016114026769 · Cited by 81 · see citing works

The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats

Pickavance, L. C., Brand, C. L., Wassermann, K., & Wilding, J. P. H. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706041 · Cited by 71 · see citing works

Growth Inhibition and Differentiation of Pancreatic Cancer Cell Lines by PPARγ Ligand Troglitazone

Kawa, S., Nikaido, T., Unno, H., Usuda, N., Nakayama, K., & Kiyosawa, K. (2002) · Pancreas · doi:10.1097/00006676-200201000-00001 · Cited by 71 · see citing works

Control of Peroxisome Proliferator‐Activated Receptor γ2 Stability and Activity by SUMOylation

Floyd, Z. E., & Stephens, J. M. (2004) · Obesity Research · doi:10.1038/oby.2004.112 · Cited by 71 · see citing works

MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response

Kilgore, M. W., Tate, P. L., Rai, S., Sengoku, E., & Price, T. M. (1997) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(97)04057-4 · Cited by 69 · see citing works

Peroxisome Proliferator-Activated Receptor γ Ligands Improve the Antitumor Efficacy of Thrombospondin Peptide ABT510

Huang, H., Campbell, S. C., Bedford, D. F., Nelius, T., Veliceasa, D., Shroff, E. H., Henkin, J., Schneider, A. J., Bouck, N., & Volpert, O. V. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.541.2.10 · Cited by 69 · see citing works

Untitled work

(2004) · PubMed · Cited by 69 · see citing works

The R -enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis

Kolluri, S. K., Corr, M., James, S. Y., Bernasconi, M., Lu, D., Liu, W., Cottam, H. B., Leoni, L. M., Carson, D. A., & Zhang, X.-K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409721102 · Cited by 68 · see citing works

Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor γ in the MCF-7 breast cancer cell line

Pignatelli, M., Cocca, C., Santos, Á., & Pérez‐Castillo, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206824 · Cited by 61 · see citing works

Troglitazone Acts on Cellular pH and DNA Synthesis through a Peroxisome Proliferator-Activated Receptor γ-Independent Mechanism in Breast Cancer-Derived Cell Lines

Turturro, F., Friday, E., Fowler, R., Surie, D., & Welbourne, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0879 · Cited by 61 · see citing works

Expression of cyclooxygenase‐2 and peroxisome proliferator‐activated receptor‐γ and levels of prostaglandin E2 and 15‐deoxy‐Δ12,14‐prostaglandin J2 in human breast cancer and metastasis

Badawi, A. F., & Badr, M. Z. (2002) · International Journal of Cancer · doi:10.1002/ijc.10770 · Cited by 60 · see citing works

The peroxisome proliferator-activated receptor γ is an inhibitor of ErbBs activity in human breast cancer cells

Pignatelli, M., Cortés‐Canteli, M., Lai, C., Santos, Á., & Pérez‐Castillo, A. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.22.4117 · Cited by 58 · see citing works

Can PPARγ Ligands Be Used in Cancer Therapy?

Rumi, M. G., Ishihara, S., Kazumori, H., Kadowaki, Y., & Kinoshita, Y. (2004) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011043352678 · Cited by 56 · see citing works

Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.

James, S. Y., Lin, F., Kolluri, S. K., Dawson, M. I., & Zhang, X.-K. (2003) · PubMed · Cited by 56 · see citing works

A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells.

Liu, D., Zang, C., Liu, H., Possinger, K., Fan, S.-G., & Elstner, E. (2004) · PubMed · Cited by 53 · see citing works

Human Adipocyte Fatty Acid-Binding Protein (aP2) Gene Promoter-Driven Reporter Assay Discriminates Nonlipogenic Peroxisome Proliferator-Activated Receptor γ Ligands

Rival, Y., Stennevin, A., Puech, L., Rouquette, A., Cathala, C., Lestienne, F., Dupont-Passelaigue, E., Patoiseau, J., Wurch, T., & Junquero, D. C. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068254 · Cited by 53 · see citing works

Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor ?? gene with breast cancer and body mass

Memisoglu, A., Hankinson, S. E., Manson, J. E., Colditz, G. A., & Hunter, D. J. (2002) · Pharmacogenetics · doi:10.1097/00008571-200211000-00003 · Cited by 43 · see citing works

A Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis

Guo, Q., Sahoo, S. P., Wang, P.-R., Milot, D. P., Ippolito, M. C., Wu, M. S., Baffic, J., Biswas, C., Hernandez, M., Lam, M., et al. (2004) · Endocrinology · doi:10.1210/en.2003-1270 · Cited by 40 · see citing works

Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents

Theocharis, S. E., Margeli, A. P., & Kouraklis, G. P. (2003) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011033482431 · Cited by 39 · see citing works

Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARγ

Hedvat, M., Jain, A., Carson, D. A., Leoni, L. M., Huang, G., Holden, S., Lu, D., Corr, M., Fox, W., & Agus, D. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.014 · Cited by 32 · see citing works

The Antiproliferative Effects of PPARγ Ligands in Normal Human Mammary Epithelial Cells

Yee, L. D., Guo, Y., Bradbury, J., Suster, S. M., Clinton, S. K., & Seewaldt, V. L. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1022978608125 · Cited by 30 · see citing works

An Intact DNA-binding Domain Is Not Required for Peroxisome Proliferator-activated Receptor γ (PPARγ) Binding and Activation on Some PPAR Response Elements

Temple, K. A., Cohen, R., Wondisford, S. R., Yu, C., Deplewski, D., & Wondisford, F. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411422200 · Cited by 29 · see citing works

Peroxisome proliferator-activated receptor β expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin

Suchanek, K. M., May, F. J., Lee, W. J., Holman, N. A., & Roberts‐Thomson, S. J. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00025-0 · Cited by 29 · see citing works

HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy.

Yang, Z., Bagheri‐Yarmand, R., Balasenthil, S., Hortobágyi, G. N., Şahin, A. A., Barnes, C. J., & Kumar, R. (2003) · PubMed · Cited by 29 · see citing works

Peroxisome Proliferator-activated Receptor-binding Protein Null Mutation Results in Defective Mammary Gland Development

Jia, Y., Qi, C., Zhang, Z., Zhu, Y. T., Rao, S. M., & Zhu, Y.-J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413331200 · Cited by 26 · see citing works

Telmisartan – killing two birds with one stone

Doggrell, S. A. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.11.2397 · Cited by 24 · see citing works

New Diagnostic Tool for Tumor Angiogenesis

Inoue, K., Kawahito, Y., Sano, H., Takano, H., & Yoshikawa, T. (2003) · CHEST Journal · doi:10.1378/chest.123.3.966-a · Cited by 4 · see citing works

Cardiac remodeling in obesity

Abel, E. D., Litwin, S. E., & Sweeney, G. (2008) · Physiological Reviews · doi:10.1152/physrev.00017.2007 · Cited by 736 · see citing works

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors

O’Sullivan, S. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707423 · Cited by 509 · see citing works

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention

Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3214 · Cited by 494 · see citing works

Enhanced angiogenesis in obesity and in response to PPARγ activators through adipocyte VEGF and ANGPTL4 production

Gealekman, O., Burkart, A., Chouinard, M., Nicoloro, S. M. C., Straubhaar, J., & Corvera, S. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90345.2008 · Cited by 174 · see citing works

Structural Basis for Activation of Fatty Acid-binding Protein 4

Gillilan, R. E., Ayers, S. D., & Noy, N. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.07.040 · Cited by 171 · see citing works

Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: Molecular mechanisms and therapeutic perspectives

Menéndez, J. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.09.005 · Cited by 157 · see citing works

Thiazolidinediones as anti-cancer agents.

Blanquicett, C., Roman, J., & Hart, C. M. (2008) · PubMed · Cited by 141 · see citing works

Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics?

Han, S., & Roman, J. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328011e67d · Cited by 135 · see citing works

Mixed Tocopherols Prevent Mammary Tumorigenesis by Inhibiting Estrogen Action and Activating PPAR-γ

Lee, H. J., Ju, J., Paul, S., So, J.-Y., DeCastro, A., Smolarek, A. K., Lee, M., Yang, C. S., Newmark, H. L., & Suh, N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3028 · Cited by 113 · see citing works

Research Resource: Nuclear Receptors as Transcriptome: Discriminant and Prognostic Value in Breast Cancer

Muscat, G. E. O., Eriksson, N. A., Byth, K., Loi, S., Graham, J. D., Jindal, S., Davis, M. J., Clyne, C. D., Funder, J. W., Simpson, E. R., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1265 · Cited by 111 · see citing works

Distinct functions for RIP140 in development, inflammation, and metabolism

Nautiyal, J., Christian, M., & Parker, M. G. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.05.001 · Cited by 94 · see citing works

The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth

Feng, Y., Velázquez-Torres, G., Gully, C. P., Chen, J., Lee, M., & Yeung, S. J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01083.x · Cited by 82 · see citing works

Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer

Caldon, C. E., Sutherland, R. L., & Musgrove, E. A. (2010) · Cell Cycle · doi:10.4161/cc.9.10.11474 · Cited by 78 · see citing works

Mitochondrial remodeling in cancer metabolism and survival: Potential for new therapies

Barbosa, I. A., Machado, N. G., Skildum, A. J., Scott, P. M., & Oliveira, P. J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.04.005 · Cited by 75 · see citing works

Obesity and Breast Cancer: The Roles of Peroxisome Proliferator‐Activated Receptor‐γ and Plasminogen Activator Inhibitor‐1

Carter, J. C., & Church, F. (2009) · PPAR Research · doi:10.1155/2009/345320 · Cited by 75 · see citing works

Coactivation of Liver Receptor Homologue-1 by Peroxisome Proliferator-Activated Receptor γ Coactivator-1α on Aromatase Promoter II and Its Inhibition by Activated Retinoid X Receptor Suggest a Novel Target for Breast-Specific Antiestrogen Therapy

Safi, R., Kovacic, A., Gaillard, S. L., Murata, Y., Simpson, E. R., McDonnell, D. P., & Clyne, C. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2792 · Cited by 70 · see citing works

The Release of Adipose Stromal Cells from Subcutaneous Adipose Tissue Regulates Ectopic Intramuscular Adipocyte Deposition

Girousse, A., Gil‐Ortega, M., Bourlier, V., bergeaud, C., Sastourné-Arrey, Q., Moro, C., Barreau, C., Guissard, C., Vion, J., Arnaud, E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.038 · Cited by 69 · see citing works

Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model

Shimazaki, N., Togashi, N., Hanai, M., Isoyama, T., Wada, K., Fujita, T., Fujiwara, K., & Kurakata, S. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.04.016 · Cited by 65 · see citing works

Cucurbitane Triterpenoid fromMomordica charantiaInduces Apoptosis and Autophagy in Breast Cancer Cells, in Part, through Peroxisome Proliferator-Activated ReceptorγActivation

Weng, J., Bai, L., Chiu, C., Hu, J.-L., Chiu, S.-J., & Wu, C.-Y. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/935675 · Cited by 65 · see citing works

Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18

Liu, H., Zang, C., Fenner, M. H., Liu, D., Possinger, K., Koeffler, H. P., & Elstner, E. (2006) · Blood · doi:10.1182/blood-2005-05-2103 · Cited by 63 · see citing works

PPARγ agonists delay age‐associated metabolic disease and extend longevity

Xu, L., Ma, X., Verma, N., Pèrié, L., Pendse, J., Shamloo, S., Josephson, A. M., Wang, D., Qiu, J., Guo, M., et al. (2020) · Aging Cell · doi:10.1111/acel.13267 · Cited by 63 · see citing works

Interleukin‐37 and Dendritic Cells Treated With Interleukin‐37 Plus Troponin I Ameliorate Cardiac Remodeling After Myocardial Infarction

Zhu, R., Sun, H., Yu, K., Zhong, Y., Shi, H., Wei, Y., Su, X., Xu, W., Luo, Q., Zhang, F., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004406 · Cited by 61 · see citing works

Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone

Cheng, W. Y., Huynh, H., Chen, P., Peña‐Llopis, S., & Wan, Y. (2016) · eLife · doi:10.7554/elife.18501 · Cited by 60 · see citing works

Ligand-activated PPARγ downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression

Rovito, D., Gionfriddo, G., Barone, I., Giordano, C., Grande, F., Amicis, F. D., Lanzino, M., Catalano, S., Andò, S., & Bonofiglio, D. (2016) · Oncotarget · doi:10.18632/oncotarget.11371 · Cited by 58 · see citing works

Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells

Pan, J., Chen, C., Jin, Y., Fuentes‐Mattei, E., Velázquez-Torres, G., Benito, J. M., Konopleva, M. Y., Andreeff, M., Lee, M., & Yeung, S. J. (2012) · Cell Cycle · doi:10.4161/cc.20770 · Cited by 56 · see citing works

PPARγ and MEK Interactions in Cancer

Burgermeister, E., & Seger, R. (2008) · PPAR Research · doi:10.1155/2008/309469 · Cited by 54 · see citing works

The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals

Nautiyal, J., Steel, J. H., Mane, M. R., Oduwole, O. O., Poliandri, A., Alexi, X., Wood, N. E. M., POUTANEN, M. H., Zwart, W. T., Stingl, J., et al. (2013) · Development · doi:10.1242/dev.085720 · Cited by 52 · see citing works

Involvement of PPARγ and E‐cadherin/β‐catenin pathway in the antiproliferative effect of conjugated linoleic acid in MCF‐7 cells

Bocca, C., Bozzo, F., Francica, S., Colombatto, S., & Miglietta, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22646 · Cited by 53 · see citing works

Modulation of PPAR-γby Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases

Ortuño‐Sahagún, D., Márquez-Aguirre, A. L., Quintero-Fabián, S., López-Roa, R. I., & Rojas-Mayorquín, A. E. (2012) · PPAR Research · doi:10.1155/2012/318613 · Cited by 54 · see citing works

PPARγ activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFβ signalling

Jarrar, M. H., & Baranova, A. V. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00003.x · Cited by 52 · see citing works

Prediction of drug-disease associations based on ensemble meta paths and singular value decomposition

Wu, G., Liu, J., & Yue, X. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2644-5 · Cited by 47 · see citing works

Activation of Peroxisome Proliferator-Activated Receptor-γ Decreases Pancreatic Cancer Cell Invasion through Modulation of the Plasminogen Activator System

Sawai, H., Liu, J., Reber, H. A., Hines, O. J., & Eibl, G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0257 · Cited by 47 · see citing works

A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia

Vu, K., Busaidy, N. L., Cabanillas, M. E., Konopleva, M. Y., Faderl, S. H., Thomas, D. A., O'Brien, S. M., Broglio, K., Ensor, J., Escalante, C. P., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.05.004 · Cited by 44 · see citing works

Disruption of ERα signalling pathway by PPARγ agonists: evidences of PPARγ-independent events in two hormone-dependent breast cancer cell lines

Lecomte, J., Flament, S., Salamone, S., Boisbrun, M., Mazerbourg, S., Chapleur, Y., & Grillier‐Vuissoz, I. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9886-z · Cited by 39 · see citing works

The non-genomic crosstalk between PPAR-γ ligands and ERK1/2 in cancer cell lines

Papageorgiou, E. G., Pitulis, N., Msaouel, P., Lembessis, P., & Koutsilieris, M. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.8.1071 · Cited by 39 · see citing works

Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer

Garattini, E., Bolis, M., Gianni’, M., Paroni, G., Fratelli, M., & Terao, M. (2016) · Oncotarget · doi:10.18632/oncotarget.7410 · Cited by 36 · see citing works

Impact of diabetes on promoting the growth of breast cancer

Chou, P., Choi, H. H., Huang, Y., Fuentes‐Mattei, E., Velazquez‐Torres, G., Zhang, F., Phan, L., Lee, J., Shi, Y., Bankson, J. A., et al. (2021) · Cancer Communications · doi:10.1002/cac2.12147 · Cited by 35 · see citing works

LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state

Furth, N., Pateras, I. S., Rotkopf, R., Vlachou, V., Rivkin, I., Schmitt, I., Bakaev, D., Gershoni, A., Ainbinder, E., Leshkowitz, D., et al. (2018) · Life Science Alliance · doi:10.26508/lsa.201800171 · Cited by 35 · see citing works

New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines

Colin, C., Salamone, S., Grillier‐Vuissoz, I., Boisbrun, M., Kuntz, S., Lecomte, J., Chapleur, Y., & Flament, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0700-y · Cited by 31 · see citing works

Induction of G 1 phase arrest and apoptosis in MDA‐MB‐231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator‐activated receptor γ (PPARγ) ligand

Yu, H., Lee, Y., Noh, E., Lee, K., Kim, J., Song, E., Han, M., Lee, Y., Kwon, K., Lee, S., et al. (2008) · Cell Biology International · doi:10.1016/j.cellbi.2008.04.011 · Cited by 30 · see citing works

Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines

Bräutigam, K., Biernath-Wüpping, J., Bauerschlag, D., von Kaisenberg, C. S., Jonat, W., Maass, N., Arnold, N., & Meinhold-Heerlein, I. M. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0952-2 · Cited by 29 · see citing works

Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor α/γ, in human breast cancer cells

Zang, C., Liu, H., Bertz, J., Possinger, K., Koeffler, H. P., Elstner, E., & Eucker, J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0347 · Cited by 29 · see citing works

PPARs in Alveolar Macrophage Biology

Smith, M. R., Standiford, T. J., & Reddy, R. C. (2007) · PPAR Research · doi:10.1155/2007/23812 · Cited by 29 · see citing works

Human Breast Cancer Xenograft Model Implicates Peroxisome Proliferator–activated Receptor Signaling as Driver of Cancer-induced Muscle Fatigue

Wilson, H. E., Rhodes, K. K., Rodríguez, D., Chahal, I. K., Stanton, D. A., Bohlen, J. F., Davis, M. C., Infante, A. M., Hazard-Jenkins, H. W., Klinke, D. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1565 · Cited by 28 · see citing works

PPARγand PPARGC1B polymorphisms modify the association between phthalate metabolites and breast cancer risk

Martínez‐Nava, G. A., Burguete-García, A. I., López‐Carrillo, L., Hernández‐Ramírez, R. U., Madrid‐Marina, V., & Cebrián, M. E. (2013) · Biomarkers · doi:10.3109/1354750x.2013.816776 · Cited by 27 · see citing works

Cytoplasmic PPARγ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers

Shao, W., Kühn, C., Mayr, D. C., Ditsch, N. C., Kailuwait, M., Wolf, V., Harbeck, N., Mahner, S., Jeschke, U., Cavaillès, V., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02271-6 · Cited by 26 · see citing works

Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells

Yu, H., Noh, E.-M., Lee, Y.-R., Roh, S., Song, E.-K., Han, M., Lee, Y.-C., Shim, I. K., Lee, S. J., Jung, S. H., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.111 · Cited by 26 · see citing works

HL005—A new selective PPARγ antagonist specifically inhibits the proliferation of MCF-7

Lü, W., Che, P., Zhang, Y., Li, H., Zou, S., Zhu, J., Deng, J., Shen, X., Jiang, H., Li, J., et al. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.01.019 · Cited by 23 · see citing works

The Lipid Side of Bone Marrow Adipocytes: How Tumor Cells Adapt and Survive in Bone

Diedrich, J. D., Herroon, M. K., Rajagurubandara, E. N., & Podgorski, I. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0453-9 · Cited by 23 · see citing works

EGR1 expression: A calcium and ERK1/2 mediated PPARγ-independent event involved in the antiproliferative effect of 15-deoxy-Δ12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells

Chbicheb, S., Xiao, Y., Rodeau, J., Salamone, S., Boisbrun, M., Thiel, G., Spohn, D., Grillier‐Vuissoz, I., Chapleur, Y., Flament, S., et al. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.006 · Cited by 22 · see citing works

Alteration of PPAR‐GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells

Esmaeili, S., Salari, S., Kaveh, V., Ghaffari, S. H., & Bashash, D. (2021) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1818 · Cited by 21 · see citing works

Enhanced Radioiodine Uptake in a Patient With Poorly Differentiated Papillary Thyroid Cancer After Treatment With Rosiglitazone

Elias, A. N., & Lizotte, P. E. (2006) · Clinical Nuclear Medicine · doi:10.1097/01.rlu.0000233148.45744.44 · Cited by 21 · see citing works

PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments

Veliceasa, D., Schulze-Hoepfner, F. T., & Volpert, O. V. (2008) · PPAR Research · doi:10.1155/2008/945275 · Cited by 20 · see citing works

Troglitazone Inhibits Matrix Metalloproteinase-9 Expression and Invasion of Breast Cancer Cell through a Peroxisome Proliferator-Activated Receptor γ-Dependent Mechanism

Hong, O., Youn, H. J., Jang, H., Jung, S. H., Noh, E., Chae, H., Jeong, Y., Kim, W. B., Kim, C., & Kim, J. (2018) · Journal of Breast Cancer · doi:10.4048/jbc.2018.21.1.28 · Cited by 19 · see citing works

Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARγ up-expression in MDA-MB-231 cells

Jiang, Y., Huang, Y., Cheng, C., Lu, W., Zhang, Y., Liu, X., Zou, L., Ben, Q., & Shen, A. (2011) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2011.09.007 · Cited by 19 · see citing works

PPARγ and PPARδ as Modulators of Neoplasia and Cell Fate

Glazer, R., Yuan, H.-Y., Xie, Z., & Yin, Y.-Z. (2008) · PPAR Research · doi:10.1155/2008/247379 · Cited by 10 · see citing works

MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice

Nogales‐Cadenas, R., Cai, Y., Lin, J.-R., Zhang, Q., Zhang, W., Montagna, C., & Zhang, Z. D. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0735-z · Cited by 17 · see citing works

Quantitative Structure‐Activity Relationships for PPAR‐γ Binding and Gene Transactivation of Tyrosine‐Based Agonists Using Multivariate Statistics

Giaginis, C., Theocharis, S. E., & Tsantili‐Kakoulidou, A. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2008.00701.x · Cited by 17 · see citing works

Human adipose-derived stem cell adipogenesis induces paracrine regulation of the invasive ability of MCF-7 human breast cancer cells in vitro

Zhao, Y., GAO, J., & Lu, F. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.1237 · Cited by 16 · see citing works

PPARγ Agonists Target Aromatase Via Both PGE2 and BRCA1

Margalit, O., Wang, D., & DuBois, R. N. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0365 · Cited by 16 · see citing works

Expression of peroxisome proliferator activated receptor γ and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma

Stadlmann, S., Gueth, U., Wight, E., Kunz‐Schughart, L. A., Hartmann, A., & Singer, G. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.035717 · Cited by 16 · see citing works

Thiazolidinedione derivatives in cancer therapy: exploring novel mechanisms, therapeutic potentials, and future horizons in oncology

Ranjan, G., Ranjan, S., Sunita, P., & Pattanayak, S. P. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03661-z · Cited by 14 · see citing works

Maresin 1 enhances osteogenic potential of mesenchymal stem cells by modulating macrophage peroxisome proliferator-activated receptor-γ-mediated inflammation resolution

Yao, D., Zou, Y., & Lv, Y. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213116 · Cited by 12 · see citing works

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes

Baranova, A. V. (2008) · PPAR Research · doi:10.1155/2008/230893 · Cited by 11 · see citing works

Effects of conjugated linoleic acid on cleavage of amyloid precursor protein via PPARγ

Li, Y., Chen, Q., Wan, X., Yang, X., Liu, X., & Zhong, L. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0711-4 · Cited by 11 · see citing works

Structural basis for the ligand-binding specificity of fatty acid-binding proteins (pFABP4 and pFABP5) in gentoo penguin

Lee, C. W., Kim, J. E., Do, H., Kim, R.-O., Lee, S. G., Park, H. H., Chang, J. H., Yim, J. H., Park, H., Kim, I., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.087 · Cited by 10 · see citing works

Indirect genomic effects on survival from gene expression data

Ferkingstad, E., Frigessi, A., & Lyng, H. (2008) · Genome biology · doi:10.1186/gb-2008-9-3-r58 · Cited by 10 · see citing works

First Evidence for a Role of Siglec-8 in Breast Cancer

Trebo, A., Ditsch, N. C., Degenhardt, T., Kühn, C., Rahmeh, M., Schmoeckel, E., Mayr, D. C., Czogalla, B., Kolben, T., Meister, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042000 · Cited by 9 · see citing works

Effect of rosiglitazone on N-nitroso-N-methylurea-induced mammary tumors in rat.

Núñez, M., Martín, G., Cocca, C., Mohamad, N. A., Gutiérrez, A., Cricco, G., Medina, V. A., Rivera, E., Croci, M., Crescenti, E. J., et al. (2006) · PubMed · Cited by 9 · see citing works

Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity

Harrer, D. C., Lüke, F., Pukrop, T., Ghibelli, L., Gerner, C., Reichle, A., & Heudobler, D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1289222 · Cited by 5 · see citing works

Effects of Maternal Grape Juice Intake on Unfolded Protein Response in the Mammary Glands of Offspring of High Fat Diet Fed Rat Dams

Dani, C., Gonçalves, L. K., Proença, I. C. T., Andrade, F. D. O., & Hilakivi‐Clarke, L. (2020) · Nutrients · doi:10.3390/nu12082253 · Cited by 5 · see citing works

A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma

Gao, D., Zhou, Q., Hou, D., Zhang, X., Ge, Y., Zhu, Q., Yin, J., Qi, X., Liu, Y., Lou, M., et al. (2024) · PeerJ · doi:10.7717/peerj.16874 · Cited by 3 · see citing works

Modification of MCF-10A Cells with Pioglitazone and Serum-Rich Growth Medium Increases Soluble Factors in the Conditioned Medium, Likely Reducing BT-474 Cell Growth

Khoo, B. Y., Miswan, N., Balaram, P., Nadarajan, K., & Elstner, E. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13055607 · Cited by 3 · see citing works

Ligands of the peroxisome proliferator-activated receptor γ inhibit hepatoce llular carcinoma cell proliferation

Jin, Z. X., Jia, B., Fu, Y., Tan, L., Chen, Q., Jiang, P., & Liu, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6731 · Cited by 3 · see citing works

Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addiction

Mascia, P., Tanda, G., Yaşar, S., Heishman, S. J., & Goldberg, S. R. (2012) · The Receptors · doi:10.1007/978-1-4614-4669-9_11 · Cited by 2 · see citing works

Glucose and antidiabetic therapy in temozolomide resistance in glioblastoma

Begagić, E., Džidić-Krivić, A., Bečulić, H., Pugonja, R., Ljevaković, A., Bašić, B., Nuhović, A., Milanović, E., Hadžić, S., Bečirović, E., et al. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i8.108112 · Cited by 1 · see citing works

Peroxisome proliferator-activated receptor gamma activator inhibits cell growth of MDA-MB-231 breast cancer cells through induction of apoptosis

Jo, E. J., Youn, H. J., & Jung, S. H. (2006) · Journal of Breast Cancer · doi:10.4048/jbc.2006.9.4.293

UWA Research Publication

Kowal, E., Pearson, G., Peacock, C. S., Jamieson, S. E., & Blackwell, J. M. (2013)

EVIDENCES - THREE PRONGED DEFENSE OF BODY AGAINST CANCER CELLS RESULTING IN CARDIAC, METABOLIC AND AUTO-IMMUNE DISORDERS

Dosaj, S., Sharma, R. K., Dosaj, U., & Basement, M. P. (2012)

ReviewArticle PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments

Veliceasa, D., Schulze-Hoepfner, F. T., & Volpert, O. V. (2008)

ReviewArticle PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes

Baranova, A. V. (2008)

Non‐Targeted Therapeutics for Inflammatory Bowel Diseases

Rogler, G. (2010) · Wiley eBooks · doi:10.1002/9781444318418.ch24

THE STROMAL ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN BREAST TUMOURIGENESIS

Skelhorne‐Gross, G. (2014) · QSpace (Queen's University Library)

F-box protein 22: A prognostic biomarker for colon cancer associated with immune infiltration and chemotherapy resistance

Lü, X., Zhang, H.-W., Chang, X., & Guo, Y.-Z. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i4.102913

LEP and FOXO1 genes, as a proposed tumor suppressor autophagic cell death related genes, can be targeted by antidiabetic therapy in nondiabetic breast cancer patients

Duran, G. A., Kiraz, Y., & Baykara, D. (2025) · Discover Oncology · doi:10.1007/s12672-025-03903-3

Effets des ligands de PPAR? sur la voie de signalisation des oestrogènes dans les cellules cancéreuses mammaires

Lecomte, J. (2009) · doi:10.70675/5c85b2d6z8af3z49beza96dz381f1cb9fa4c

Etude du facteur de transcription précoce EGR1 dans l'effet antiprolifératif des ligands de PPAR[gamma] sur les cellules cancéreuses mammaires

Chbicheb, S. (2011) · doi:10.70675/c813cb91z3c60z4c53z8342z9a5179f2d43b

Innovation moléculaire à visée thérapeutique : conception, synthèse et évaluation des propriétés anticancéreuses de nouveaux dérivés du (N-(5-méthyl)-quinoléin-8-ol)amine N-substitués

Madonna, S. (2010) · doi:10.70675/659c82ebzed88z45f4zbdb9z0440a121a800

Antitumorigenic mechanisms of action of peroxisome proliferator-activated gamma (ppargamma) ligands in breast cancer

Pérez, J. D. (2009) · Dialnet (Universidad de la Rioja)

The effects of rosiglitazone therapy in early stage breast cancer

Yee, L. D., Williams, N., Wen, P., Young, D. C., Lester, J., Johnson, M. V., Farrar, W. B., Walker, M. J., Povoski, S. P., Suster, S. M., et al. (2006) · Cancer Research

Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers

Yee, L. D., Williams, N., Wen, P., Young, D. C., Lester, J., Johnson, M. V., Farrar, W. B., Walker, M. J., Povoski, S. P., Suster, S. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1947 · Cited by 98 · see citing works

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes

Baranova, A. V. (2008) · PPAR Research · doi:10.1155/2008/230893 · Cited by 11 · see citing works

GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation

Seargent, J. M., Yates, E., & Gill, J. H. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705973 · Cited by 193 · see citing works